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Parkinson’s disease (PD) is a sporadic progressive neurodegenerative brain disorder with
a relatively strong genetic background. We have reviewed the current literature about the
genetic factors that could be indicative of pathophysiological pathways of PD and their
applications in everyday clinical practice. Information on novel risk genes is coming from
several genome-wide association studies (GWASs) and their meta-analyses. GWASs
that have been performed so far enabled the identification of 24 loci as PD risk factors.
These loci take part in numerous cellular processes that may contribute to PD pathology:
protein aggregation, protein, and membrane trafficking, lysosomal autophagy, immune
response, synaptic function, endocytosis, inflammation, and metabolic pathways are
among the most important ones. The identified single nucleotide polymorphisms
are usually located in the non-coding regions and their functionality remains to be
determined, although they presumably influence gene expression. It is important to be
aware of a very low contribution of a single genetic risk factor to PD development;
therefore, novel prognostic indices need to account for the cumulative nature of genetic
risk factors. A better understanding of PD pathophysiology and its genetic background
will help to elucidate the underlying pathological processes. Such knowledge may help
physicians to recognize subjects with the highest risk for the development of PD, and
provide an opportunity for the identification of novel potential targets for neuroprotective
treatment. Moreover, it may enable stratification of the PD patients according to their
genetic fingerprint to properly personalize their treatment as well as supportive measures.
Keywords: Parkinson’s disease, genetic risk factors, genome-wide association studies, single nucleotide
polymorphisms, personalized medicine
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative brain disease after
Alzheimer’s disease. It is believed that both genetic and environmental factors contribute to the
development of PD. It is a chronic, progressive and incurable disease (Pringsheim et al., 2014).
Two pathological hallmarks characterize PD: the formation of cytoplasmic inclusions termed Lewy
bodies and Lewy neurites and the loss of dopaminergic neurons in the substantia nigra pars
compacta (Gallegos et al., 2015). The disease manifests as bradykinesia, muscular rigidity, rest
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tremor and postural and gait impairment (Postuma et al., 2015),
which can be accompanied by several other nonmotor symptoms
(Gallegos et al., 2015). At the present time, there is unfortunately
no cure for PD except for the symptomatic treatment and
supportive measures (Connolly and Lang, 2014).
Two different forms of PD have been identified, i.e., sporadic
and familial. The familial form starts at an earlier stage of life
(<50 years), is usually more severe and progresses more quickly
(Klein and Westenberger, 2012). At early stages of research
on genetics of PD, only linkage studies were performed, which
means that families with PD history were included in the study.
These studies identified mutations in six genes that conclusively
cause monogenic PD—SNCA, LRRK2, Parkin, PINK1, DJ-1,
ATP13A2 (Klein and Westenberger, 2012).
In this review, we focus mainly on the sporadic form of the
disease. However, there is some overlap between genes associated
with familial and sporadic disease; in particular, SNCA and
LRRK2 are involved in both forms (Verstraeten et al., 2015; van
der Brug et al., 2015). Recently, genome-wide association studies
(GWASs) that compared single nucleotide polymorphisms’
(SNPs) frequencies between sporadic PD patients and healthy
individuals have identified several loci as Parkinson’s disease
susceptibility genes (Klein and Westenberger, 2012; Nalls et al.,
2014). A few of these loci, 24 in particular, harboring SNPs
that were found to be associated with PD were validated in
the replication phase of the latest and largest meta-analysis of
GWASs performed by Nalls et al. in 2014. In the discovery
phase, they performed a meta-analysis of GWASs including
13,708 cases and 95,282 controls chosen from the populations
of European descent (the USA, France, Germany, Iceland,
the Netherlands, the UK; 23 and Me), while the replication
phase of the study included 5,353 cases and 5,551 controls
(Nalls et al., 2014). The identified loci segregate with numerous
cellular pathways that may contribute to PD pathology: protein
aggregation, protein, and membrane trafficking, lysosomal
autophagy, immune response, synaptic function, endocytosis,
inflammation, and metabolic pathways being among the most
important ones (Kumaran and Cookson, 2015). Each locus
identified as a risk factor has a rather low contribution to
PD development; therefore, a combination of molecular defects
rather than a single event probably plays a role in PD risk, hence
the idea of a cumulative nature of genetic risk factors (Pihlstrom
et al., 2016).
This review summarizes the latest knowledge on genetics and
genomics of PD susceptibility, obtained by GWASs and their
meta-analyses. We focus on the largest meta-analysis of GWASs
on PD risk so far (Nalls et al., 2014), but we also searched the
PubMed database and GWAS catalog (Welter et al., 2014) for
studies that pointed out the same loci as the above-mentioned
meta-analysis. We identified 13 GWASs and their meta-analyses
(summarized in Table 1), which we included in this review. We
compiled the available data on the 24 loci that were found to
be associated with the risk of sporadic form of PD. To obtain
the information about gene functions, we searched the PubMed
database and collected the available data on genes’ functions
with the help of the following words: “Parkinson’s disease
and gene name” or “Parkinson’s disease and polymorphisms
and gene name.” We divided the susceptibility genes into
seven groups according to their physiological functions: protein
aggregation; protein, and membrane trafficking; lysosomal
autophagy; immune system; neurodevelopment, neuron cell
differentiation, and survival; mitochondrial homeostasis; and
genes involved in other processes. This review highlights the
main functions of these genes’ products and their role in the PD
pathogenesis.
GENETIC DETERMINANTS OF RISK FOR
SPORADIC PD AND THEIR IMPLICATED
PATHWAYS
Protein Aggregation
The products of the genes listed below, i.e., SNCA and tau, are
both constituents of the protein aggregates typical of PD called
Lewy bodies. PD is often thought to be a prion-like disease
because of the presence of these bodies (Hasegawa et al., 2016).
SNCA
SNCA codes for α-synuclein (SNCA), which is a small, acidic
protein of 14.5 kDA and 140 amino acids (Gallegos et al., 2015).
It is the main component of aggregates called Lewy bodies, a
hallmark of PD pathology. Lewy bodies are formed because a
mutated protein usually adopts the β-sheet structure, which is
harder to degrade than α-helixes, the main conformation of
native proteins (Gallegos et al., 2015; Inoshita and Imai, 2015).
Different variants of the gene have been connected to both
familial and sporadic forms of PD. Several studies on families
with positive PD history have reported the association of SNCA
with PD, the first one being published in 1997 by Polymeropoulos
et al. (1997). The association with sporadic PD was first described
by Kruger et al. who compared the allelic frequences of REP1
polymorphism in the promoter region of SNCA between cases
and controls (Kruger et al., 1999). This association was later
confirmed on a larger set of data (Maraganore et al., 2006).
The majority of GWASs performed also confirmed SNCA as
a susceptibility gene (Satake et al., 2009; Simon-Sanchez et al.,
2009; Edwards et al., 2010; Hamza et al., 2010; Do et al., 2011;
Nalls et al., 2011, 2014; Saad et al., 2011; Spencer et al., 2011;
Lill et al., 2012; Pankratz et al., 2012; Hill-Burns et al., 2014).
To date, over 800 SNPs within SNCA have been reported, with
nearly half of them showing a positive association with PD
(Kumaran and Cookson, 2015). SNPs within SNCA recognized
as PD susceptibility factors by GWASs are listed in Table 2. The
most replicated SNP rs256220 was confirmed as a risk factor
in six studies, whereas several others were found in only one
or two studies. Some SNCA mutations can cause both sporadic
and familial forms of PD. These are usually more penetrant
(Singleton et al., 2013). Besides point mutations—Ala53Thr,
Ala30Pro, and Glu46Lys in the amino-terminal sequence, whole
locus multiplications (duplications and triplications) were also
found in both forms (Bisaglia et al., 2009).
SNCA is widely expressed in the central nervous system,
especially in the presynaptic terminals of neurons (Inoshita and
Imai, 2015). It has two main physiological roles, the first being
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TABLE 1 | GWAS studies and their meta-analyses that identified 24 risk loci included in this review.
Study Ancestry Number of cases
Initial phase
(cases vs. controls)
Replication phase
(cases vs. controls)
Nalls et al., 2014# European
Initial phase—*USA, *France, *Germany, *Iceland,
*Netherlands, *UK, *23andMe
Replication phase—*US, *UK, *France,
*Germany, *Greece, *Netherlands, *NeuroX
13,708 vs. 95,282 5,353 vs. 5,551
Vacic et al., 2014 Ashkenazi Jewish
Initial phase—*Israel, *US
Replication phase—*Israel, *US
1,130 vs. 2,611 306 vs. 2,583
Hill-Burns et al., 2014 European
Initial phase—*US
Replication phase—not reported
1,565 sporadic cases + 435
familial cases vs. 1,986 controls
1,528 sporadic cases +
707 familial cases vs. 796
controls
Lill et al., 2012# Initial phase—*US
Replication phase—European and Asian
2,197 vs. 2,061 Up to 98,080
Pankratz et al., 2012# European 4,238 vs. 4,239 3,738 vs. 2,111
Do et al., 2011 European 3,426 vs. 29,624 Not applicable
Nalls et al., 2011# Initial phase—*France, *Germany, *UK, *US
Replication phase—*US, *France, *Germany,
*Netherlands, *Iceland, *UK
5,333 vs. 12,019 7,053 vs. 9,007
Hamza et al., 2010 European 2,000 vs. 1,986 Up to 1,447 vs. 1,468
Saad et al., 2011 European 1,039 vs. 1,984 3,232 vs. 7,064
Spencer et al., 2011 Initial phase—*UK
Replication phase—*France
1,705 vs. 5,175 1,039 vs. 1,984
Edwards et al., 2010 European 1,752 vs. 1,745 Not applicable
Satake et al., 2009 Japanese 988 vs. 2,521 933 vs. 15,753
Simon-Sanchez et al., 2009 European 1,713 vs. 3,978 3,361 vs. 4,573
*country of recruitment, if specified.
#meta-analysis.
Data compiled from the GWAS catalog database and PDgene (Lill et al., 2012; Nalls et al., 2014; Welter et al., 2014).
the control of synaptic membrane processes and the second
being the control of neurotransmitter release via interactions
withmembers of the SNARE family (Bellucci et al., 2012; Tsigelny
et al., 2012). It promotes SNARE-complex assembly through
a non-enzymatic mechanism, binding to phospholipids via its
N-terminal and to synaptobrevin-2 via its C-terminal (Burre
et al., 2010). SNCA is deeply involved in the synaptic vesicle
cycle, including trafficking, docking, fusion, and recycling after
exocytosis. It was also suggested that SNCA is a negative regulator
of neurotransmitter release, including dopamine, with traffic
restriction of synaptic vesicles from the resting pool to the sites
of release (Emanuele and Chieregatti, 2015).
Wild-type SNCA is translocated to the lysosomes for
degradation via chaperone-mediated autophagy via the
lysosomal membrane receptor LAMP2A (Gan-Or et al., 2015).
Lysosomal enzyme β-glucocerebrosidase (GBA) then modulates
SNCA levels (Klein and Westenberger, 2012). Mutant SNCA
somehow inhibits chaperone-mediated autophagy, presumably
by attaching to the LAMP2A and preventing its internalization
of wild-type and mutant SNCA. Recently, it has been shown that
GBA and SNCA form a positive feedback loop that leads to the
accumulation of SNCA. The loss of GBA function results in the
accumulation of SNCA, whereas SNCA inhibits the lysosomal
activity of GBA (Mazzulli et al., 2011).
SNCA is presumably also involved in dopamine release and in
the synaptic vesicle dynamics, especially in the recycling pathway.
The excess of SNCA reduces the recycling of synaptic vesicles and
their motility (Inoshita and Imai, 2015). Furthermore, it has been
confirmed that dopamine can interact with the SNCA molecule
via the C-terminal residues which can induce and/or modulate
its structure and oligomerization. As a result dopamine blocks
chaperone-mediated autophagy of SNCA. This may explain why
dopaminergic neurons are more prone to SNCA accumulation
(Bellucci et al., 2012; Lashuel et al., 2013; Gan-Or et al., 2015).
SNCA also modulates dopamine vesicle trafficking by other
mechanisms. According to Ahn et al. SNCA binds and
consequently inhibits phospholipase D2 (PLD2), which is
involved in vesicle trafficking in terms of endo- and exocytosis
(Ahn et al., 2002). SNCA’s interacting partner is also actin
which is essential for synaptic vesicle mobilization between
different functional pools. SNCA binding modulates actin’s
polymerization in a manner dependent on Ca2+ concentration
(Bellani et al., 2010). Intracellular Ca2+ concentration may also
change due to the formation of pore-like structures in the cell
membranes bymutant SNCA (Lashuel et al., 2002). Furthermore,
SNCA’s interacting partner is also a rate-limiting enzyme in
the dopamine synthesis, tyrosine hydroxylase (TH), responsible
for the conversion of tyrosine to L-3,4-dihydroxyphenylalanine
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TABLE 2 | SNPs within loci associated with protein aggregation recognized as PD susceptibility factors by GWASs.
Gene/locus Chromosome SNP MAF (1000 genomes project) Risk allele: OR Study
SNCA Ch 4 rs356182 g.90626111G>A (intron variant) G = 0.4044 G: OR = 1.32 Nalls et al., 2014
rs356219 g.90637601G>A (intron variant) A = 0.4892 OR = 1.29 Lill et al., 2012
G: OR = 1.29 Nalls et al., 2011
rs356220 g.90641340T>C (intron variant) C = 0.4834 OR = 1.38 Pankratz et al., 2012
T: OR = 1.29 Do et al., 2011
T: OR = 1.27 Spencer et al., 2011
T: OR = 1.38 Hamza et al., 2010
T: OR = 1.38 Hill-Burns et al., 2014
T: OR = 1.37 Saad et al., 2011
rs11931074 g.90639515G>T (intron variant) T = 0.3806 OR = 1.37 Satake et al., 2009
rs2736990 g.90678541G>A c.307-28113C>T
(intron variant)
A = 0.3934 G: OR = 1.23 Simon-Sanchez et al., 2009
OR = 1.29 Edwards et al., 2010
rs6532194 g.90780902C>T (intergenic variant) T = 0.3694 OR = 1.29 Lill et al., 2012
MAPT Ch 8 rs17649553 g.43994648C>T (intron variant) T = 0.0865 C: OR = 1.3 Nalls et al., 2014
900 kb inversion H1/H2 Lill et al., 2012
rs2942168 g.43714850C>T (intron variant) A = 0.0863 G: OR = 1.27 Nalls et al., 2011
rs393152 g.43719143A>G (intron variant) G = 0.2476 A: OR = 1.3 Simon-Sanchez et al., 2009
rs12185268 g.43923683A>G p.Ile471Val
(missense variant)
G = 0.0863 A: OR = 1.3 Do et al., 2011
rs8070723 g.44081064A>G
c.1828-6612A>G (intron variant)
G = 0.1190 OR = 1.3 Spencer et al., 2011
rs17577094 g.44187492A>G
c.1290-15425T>C (intron variant)
G = 0.0865 OR = 1.56 Vacic et al., 2014
rs11012 g.43513441C>T c.*1783G>A T = 0.0807 T: OR = 1.43 Edwards et al., 2010
rs199498 g.46788237T>C c.81-14328A>G
(intron variant)
C = 0.2578 T: OR = 1.35 Hill-Burns et al., 2014
rs199533 g.44828931G>A p.Lys702 =
(synonimous variant)
A = 0.0791 C: OR = 1.35 Hamza et al., 2010
Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
*Denotes SNPs in 3’-UTR.
(L-DOPA). This interaction inhibits the phosphorylation of TH
and thus also its action (Venda et al., 2010).
SNCA is also linked to neuroinflammation. In mice with
aggregated SNCA, MHCII expression is induced in microglia.
Moreover, SNCA as a danger-associated molecular pattern
(DAMP) stimulates toll-like receptors (TLR). Misfolded and
fibrillar SNCA activates microglia via TLR2 and TLR4 and
activation of NLRP3 inflammasome (Gustot et al., 2015). These
processes contribute to dopaminergic neuronal death (Dzamko
et al., 2015; Kumaran and Cookson, 2015).
In addition, SNCA mutations can lead to dysfunctions in
several other cellular pathways, such as mitochondrial function,
oxidative stress, cytochrome c release, ER stress, apoptosis
(Gallegos et al., 2015).
MAPT
MAPT encodes a microtubule-associated protein tau, which has
a role in stabilizing microtubules in the neurons. The gene was
first recognized as a PD risk factor by Pastor et al. (2000). It
has been repeatedly confirmed as a risk factor for sporadic PD
by GWASs and their meta-analyses (Simon-Sanchez et al., 2009;
Edwards et al., 2010; Hamza et al., 2010; Do et al., 2011; Nalls
et al., 2011, 2014; Spencer et al., 2011; Lill et al., 2012; Hill-Burns
et al., 2014; Vacic et al., 2014), but each variant has only been
pointed out once and has not been replicated in other studies.
More than 40 mutations have been discovered to date. They are
either coding mutations, that affect the binding activity of the
tau or its susceptibility to aggregation, or mutations that alter
the splicing of exon 10 which encodes the fourth microtubule
binding repeat (4R tau isoforms) (Wray and Lewis, 2010).
Mutations within MAPT locus recognized as PD susceptibility
factors by GWASs are listed in Table 2. The MAPT locus is the
longest region of linkage disequilibrium in Caucasians. There are
two variants of the locus resulting from an inversion of a 900 kb
long portion of the sequence, which leads to two haplotypes—
H1 and H2. MAPT H1 haplotype increases the transcription of
the gene, whereas MAPT H2 haplotype decreases it (Golpich
et al., 2015). The inversion is present in the H2 haplotype,
which has a 20% frequency in the Caucasians, but is almost not
present in the Asian population (Wider et al., 2010; Schulte and
Gasser, 2011; Soto-Ortolaza and Ross, 2016). MAPT association
was not replicated in the Japanese population probably due to
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inter-population heterogeneity at this locus (Satake et al., 2009;
Labbé and Ross, 2014). H1 haplotype is more dynamic and can
be subdivided into subhaplotypes. Homozygous MAPT H1/H1
genotype is a biomarker of dementia in PD (Lin and Wu,
2015). As H1 haplotype is associated with a greater risk of PD
and other neurodegenerative diseases, it may be assumed that
H2 haplotype is under positive selection (Schulte and Gasser,
2011). Polymorphisms in the MAPT gene are also involved
in the pathologies of Alzheimer’s disease (AD), progressive
supranuclear palsy (PSP), and corticobasal degeneration (CBD)
(Vandrovcova et al., 2009).
MAPT encoded protein tau is a potential component
of Lewy bodies. In PD patients with a more pronounced
cognitive decline, neurofibrillary tangles, more typical of AD,
can also be found besides Lewy bodies. These tangles consist
of hyperphosphorylated tau (Horvath et al., 2013; Lin and
Wu, 2015). Physiologically, phosphorylation of the tau protein
regulates its propensity to interact with microtubules (Wray and
Lewis, 2010). According to some studies, SNCA also promotes
tau fibrillization and influences tau phosphorylation (Giasson
et al., 2003). The interplay between the two genes was also
confirmed by the study of Goris et al., reporting nearly a double
risk of PD in carriers of the combined MAPT H1/H1 and
SNCA rs356219 G/G genotype (Goris et al., 2007). Most of the
pathological changes in the MAPT sequence disrupt the ability
of tau to interact with microtubules (Wray and Lewis, 2010). Tau
is also fundamental for the maintenance of cytoskeletal network
via the regulation of axonal transport by interactions with kinesin
and dynein (Kumaran and Cookson, 2015).
Mutated MAPT may also affect the function of lysosomes
and its role in autophagy, since it is degraded with this process
(Gan-Or et al., 2015).
MAPT gene lies in a block of nearly complete linkage
disequilibrium that extends over nearly 2 Mb, therefore it is
possible that other genes from this region are also associated with
PD risk (Charlesworth et al., 2012). For example, a variant in
the CRHR1 gene coding for the corticotropin-releasing hormone
receptor has recently been recognized as a factor that decreases
the PD susceptibility (Davis et al., 2016).
Protein and Membrane Trafficking
SNPs within loci associated with protein and membrane
trafficking recognized as PD susceptibility factors by GWASs
are listed in Table 3. The genes within this group are involved
in processes, such as clathrin-mediated vesicular transport,
trafficking, and fusing of synaptic vesicles, clearance of Golgi-
derived vesicles, endo- and exocytosis and protein sorting.
TMEM175/GAK/DGKQ
A haplotype block TMEM175/GAK/DGKQ (transmembrane
protein 175/cyclin G associated kinase/theta diacylglicerol
kinase) was first associated with sporadic PD in the GWAS
performed by Hamza et al. after it was already confirmed to be
associated with the familial form of the disease (Pankratz et al.,
2009; Hamza et al., 2010). This locus was reevaluated several
times by different research groups and also showed positive
results in other GWASs and meta-analyses of GWASs. The most
replicated SNP is an intron variant rs11248060, others were
found in individual studies only (Edwards et al., 2010; Do et al.,
2011; Nalls et al., 2011, 2014; Lill et al., 2012; Pankratz et al., 2012).
GAK is a particularly promising candidate for a risk gene,
because it is differentially expressed in the substantia nigra pars
compacta of PD patients as compared to controls (Pankratz
et al., 2009). GAK gene product participates in multiple steps
of clathrin-mediated vesicular transport. For example, together
with the heat-shock cognate protein 70 (Hsc70), it promotes
the uncoating of endocytosed clathrin-coated vesicles. Probably
it has also some other functions related to its serine/threonine
kinase domain. It also directly interacts with LRRK2 and
participates in the clearance of Golgi-derived vesicles via the
lysosomal autophagy pathway as a part of LRRK2/RAB7L1/GAK
trans-Golgi complex (Kumaran and Cookson, 2015; Perrett
et al., 2015). Recently, depletion of GAK has been shown to
influence lysosomal sorting of cathepsin D, the main lysosomal
enzyme involved in SNCA degradation (Latourelle et al., 2009).
Knockdown of GAK in primary rat neurons increased SNCA
toxicity (Perrett et al., 2015). GAK also takes part in cell cycle
regulation (Labbé and Ross, 2014).
Less is known about DGKQ; however, it is expressed in the
brain where it may be involved in the phosphatidylinositol and
lipid signaling (Pankratz et al., 2009). DGK proteins are also
known to affect Ca2+ signaling as well as the trafficking and
fusing of synaptic vesicles at nerve terminals in the central
nervous system (Ran and Belin, 2014).
NUCKS1/RAB7L1
A haplotype block NUCKS1/RAB7L1 (nuclear casein kinase
and cyclin-dependent kinase substrate 1/RAB7, member RAS
oncogene family-like 1) is in linkage disequilibrium and is also
known by the name PARK16 locus. This locus contains five
genes—SLC45A3, NUCKS1, RAB7L1, SLC41A1, and PM20D1.
The association between PD and NUCKS1 was first described in
the GWAS conducted by Simon-Sanchez et al. (2009), whereas
the association with RAB7L1 was first shown in Satake et al.
GWAS (Satake et al., 2009). The implication of this locus in PD
was then again confirmed in meta-analysis of GWASs by Nalls
et al. and in the GWAS by Vacic et al. (Nalls et al., 2014; Vacic
et al., 2014). Four SNPs were pointed out by genome-wide studies
in this locus but none of them was replicated.
RAB7L1, also named RAB29, is a cytoplasmic GTP-binding
protein, which plays an important role in endo- and exocytosis.
Exocytosis is relevant in PD because dopamine is released
via exocytotic vesicles and because it has been shown that
vesicle abnormalities occur in SNCA knock-out mice (Plagnol
et al., 2011). RAB7L1 is one of the LRRK2 interacting
partners in the process of removal of Golgi derived vesicles by
autophagy-dependent mechanisms. RAB7L1 deficiency caused
neurodegeneration in mammalian or Drosophila dopaminergic
neurons having a human LRRK2 mutation, while RAB7L1
overexpression restored the function of LRRK2 mutant neurons.
MacLeod et al. showed that expressing mutant LRRK2 or
reducing the expression of RAB7L1 in a cell line led to the
loss of components of the retromer complex, which regulates
protein sorting from the lysosome to the Golgi apparatus.
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TABLE 3 | SNPs within loci associated with protein and membrane trafficking recognized as PD susceptibility factors by GWASs.
Gene/locus SNP MAF (1000 genomes project) Risk allele: OR Study
TMEM175/GAK/DGKQ Ch 4 rs34311866 g.951947T>C p.Met311Thr (missense
variant)
C = 0.1400 C: OR = 1.27 Nalls et al., 2014
rs11248060 g.964359C>T (intron variant) T = 0.1066 OR = 1.21 Lill et al., 2012
OR = 1.26 Pankratz et al., 2012
NA Edwards et al., 2010
rs6599388 g.939087C>T (intron variant) T = 0.3243 T: OR = 1.16 Nalls et al., 2011
rs11248051 g.858332C>T (intron variant) T = 0.0966 T: OR = 1.46 Hamza et al., 2010
rs6599389 g.939113G>A (intron variant) A = 0.1092 A: OR = 1.31 Do et al., 2011
NUCKS1/RAB7L1 Ch 1 rs823118 g.205723572C>T (upstream gene
variant)
T = 0.4111 T: OR = 1.122 Nalls et al., 2014
rs947211 g.205752665A>G (intergenic variant) A = 0.4613 OR = 1.3 Satake et al., 2009
rs823128 g.205713378G>A (intron variant) G = 0.1765 A: OR = 1.52 Simon-Sanchez et al., 2009
rs823114 g.205719532G>A c.-431C>T (upstream
gene variant)
A = 0.4073 OR = 1.33 Vacic et al., 2014
LRRK2 Ch 12 rs76904798 g.40614434C>T (intron variant) T = 0.1318 T: OR = 1.155 Nalls et al., 2014
rs34637584 g.40734202G>A p.Gly2019Ser
(missense variant)
A = 0.0002 A: OR = 9.62 Do et al., 2011
rs1442190 g.41365640G>A c.*325G>A A = 0.0747 OR = 3.72 Vacic et al., 2014
rs34778348 g.40757328G>A p.Gly2385Arg
(missense variant)
A = 0.0048 OR = 2.23 Lill et al., 2012
rs1491942 g.40620808C>G c.237+1366C>G
(intron variant)
G = 0.2979 OR = 1.17 Lill et al., 2012
G: OR = 1.27 Nalls et al., 2011
rs1994090 g.40428561G>T c.717-6250C>A
(intron variant)
G = 0.1472 OR = 1.39 Satake et al., 2009
INPP5F Ch 10 rs117896735 g.121536327G>A c.179-4820G>A
(intron variant)
A = 0.0040 A: OR = 1.624 Nalls et al., 2014
BCKDK/STX1B Ch 16 rs14235 g.31110472G>A c.615G>A p.Thr205 =
(synonymous variant)
A = 0.3592 A: OR = 1.103 Nalls et al., 2014
VPS13C Ch 15 rs2414739 g.61701935G>A (intron variant) G = 0.3209 A: OR = 1.113 Nalls et al., 2014
NA, data not available; Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
*Denotes SNPs in 3’-UTR.
Secondary to these changes, the swelling of lysosomes and the
reduction of lysosomal mannose 6-phosphate receptor (M6PR)
accumulation occur (MacLeod et al., 2013; Perrett et al., 2015).
M6PRs are needed for the recruitment and transport of lysosomal
hydrolases to the lysosome; therefore, the disruption of this
functionmay lead to lysosomal dysfunction (Gan-Or et al., 2015).
RAB7L1 thus functions downstream of GAK in the retromer
sorting process (Hoang, 2014). The authors also suggested an
epistatic effect, with nonlinear increase in PD susceptibility when
both risk alleles are present in the patient’s DNA sequence
(MacLeod et al., 2013).
Less is known about NUCKS1 and its involvement in PD
pathogenesis. NUCKS1 is a nuclear protein containing several
consensus phosphorylation sites for casein kinase II and cyclin-
dependent kinases of unknown function (Satake et al., 2009).
According to some studies, NUCKS1 might also be involved in
inflammation and immunity (Dzamko et al., 2015). The recent
GWAS meta-analysis has reported that rs823118 was tagged
an expression quantitative trait locus and also a methylation
quantitative trait locus for both RAB7L1 and NUCKS1 (Wang
et al., 2016).
LRRK2
LRRK2 (leucine-rich repeat kinase 2) gene was first described
as a risk factor for the familial form of PD, but was later
also confirmed as sporadic PD susceptibility gene by GWASs.
It encompasses rare highly penetrant variants as well as more
common variants with a lower effect (van der Brug et al., 2015).
LRRK2 mutations are the most common gene defect in sporadic
PD (Perrett et al., 2015). The first GWAS that confirmed LRRK2
as a risk factor for sporadic PD was performed by Satake et al.
(2009). Later, its association with PD was also confirmed in other
GWASs and their meta-analyses (Do et al., 2011; Nalls et al., 2011,
2014; Lill et al., 2012; Vacic et al., 2014). Six different SNPs were
found by GWASs as risk factors, but only one (rs1491942) was
also replicated in a later study (Lill et al., 2012). LRRK2 accounts
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for a large part of risk for sporadic PD in some populations—
Ashkenazi Jews, Arabs, East Asians. Coding variability at the
LRRK2 locus explains 10% of PD risk in these populations. In the
outbred Europeans, LRRK2 and GBA account for around 8% of
risk. Carriers of LRRK2 mutations usually have Lewy bodies, the
minority has also tangles, but some of them have neither (Hardy,
2010).
LRRK2 is a multidomain protein that has a GTPase and kinase
function as well as many protein/protein interaction motifs.
It is expressed in axons and dendrites in the striatum and
the cortex, but expression is low in nigral cell bodies. LRRK2
seems to regulate actin complexes, vesicle trafficking, endosome
maturation, cytoskeletal dynamics, and protein translation
(Volta et al., 2015). It was detected as a binding partner of the
late-endosomal marker Rab7 and also as a binding partner of
the lysosomal marker LAMP2A, which generated the idea that
it has an important function in the endo-lysosomal pathway.
Mutant LRRK2-RAB7 colocalization can lead to a reduced
RAB7 function and impaired late endosomal trafficking events.
LRRK2 also interacts with RAB7L1 to modify protein sorting.
It also binds the PD susceptibility factor GAK in a complex
that promotes removal of Golgi derived vesicles by autophagy-
dependent mechanisms (Perrett et al., 2015). It is tightly linked
to endocytotic and exocytotic processes required for rapid
synaptic vesicles and receptor recycling via interaction with
clathrin (Volta et al., 2015). It regulates endophilin association
to clathrin-coated vesicles through phosphorylation (Drouet
and Lesage, 2014). Furthermore, it influences the action of
EndoA via phosphorylation, a protein important for endocytic
synaptic vesicles recycling (Inoshita and Imai, 2015). Moreover,
LRRK2 is involved in mitochondrial membrane maintenance
via fusion/fission processes and in lysosomal autophagy and
recycling of V-ATPase required for lysosomal acidification
(Ryan et al., 2015; Volta et al., 2015). The dysregulation of
mitochondrial function can also be caused by the inhibition of
the endogenous peroxidase phosphorylation by mutant LRRK2
(Saiki et al., 2012). LRRK2 also has a role in neuroinflammation
by increasing the cytokine release from activated primary
microglial cells, which results in neurotoxicitiy (Russo et al., 2014;
Blesa et al., 2015). Moreover, it interferes with the translation
machinery by phosphorylation of several proteins, for example
translation repressor protein 4E-BP (Taymans et al., 2015).
Among PD patients having the LRRK2 mutation, the most
common one is p.Gly2019Ser (rs34637584). The penetrance is
high—50% at the age of 50 and 74% at the age of 79. This
mutation is located in the kinase domain resulting in an increase
in the activity (Wallings et al., 2015). 1.6% of sporadic PD patients
possess this mutation (Satake et al., 2009). Mutated LRRK2
(p.Gly2019Ser) actually binds to outer mitochondrial membrane,
which leads to a decrease in mitochondrial membrane potential
and to a decrease in the intracellular ATP level. On the contrary,
mitochondrial elongation and interconnectivity were elevated
(Subramaniam and Chesselet, 2013).
INPP5F
Inositol polyphosphate-5-phosphatase F (INPP5F), one of the
polyphosphoinositide phosphatases, was first described as a PD
risk factor in a meta-analysis carried out by Nalls et al. in 2014
(Nalls et al., 2014), which means that only one SNP was found to
be associated with PD susceptibility so far. The gene’s product is
supposed to be involved in the endocytic pathways. It contains
a Sac domain, which is involved in the endocytosis of synaptic
vesicles (Inoshita and Imai, 2015; Nakatsu et al., 2015). The
knowledge about the gene’s function is limited and on the basis
of only one study pointing out the association, we cannot reach
any conclusions as to the main role of the gene in PD pathology
and the actual association.
BCKDK/STX1B
BCKDK/STX1B (branched chain ketoacid dehydrogenase
kinase/syntaxin 1B) locus was established as a PD risk factor in
GWAS meta-analysis by Nalls et al. Only one SNP (rs14235)
is known to be associated with PD, thus replication studies are
needed to confirm the actual association (Nalls et al., 2014).
BCKDK is located in the mitochondrial matrix and plays
a major role in valine, leucine and isoleucine catabolism. Its
function is phosphorylation and thus inactivation of the BCKD.
BCKD concentration is the same in all tissues, whereas BCKDK
concentration varies. BCKD’s level of function is thus regulated
by BCKDK (García-Cazorla et al., 2014).
STX1B codes for syntaxin 1B, which functions as a synaptic
receptor for vesicle transport. It was previously shown to be
directly implicated in the process of calcium-dependent synaptic
transmission in rat brain, having been suggested to play a role in
the excitatory pathway of synaptic transmission (Plagnol et al.,
2011). It plays a role in dopamine neurotransmission (Kalia and
Lang, 2015).
VPS13C
Vacuolar protein sorting 13 homolog C (VPS13C) was shown
to be associated with PD as a risk factor only in the meta-
analysis by Nalls et al. (2014). First, it was considered only as a
risk factor for sporadic PD, but it has recently been discovered
that it could also cause the familial autosomal-recessive early-
onset form of PD with a very severe course of the disease
(Lesage et al., 2016). The gene has two variants, variant 2 being
specific to brain tissue (Velayos-Baeza et al., 2004). It functions
in the vesicular transport, more specifically endosomal transport
pathway (Inoshita and Imai, 2015). Functional studies of the
protein are lacking, but a very recent one also suggests a protein
quality control function (Yang et al., 2016). More association and
functional studies will have to be conducted to be completely
confident of the gene’s role in PD susceptibility and pathology.
Lysosomal Autophagy
SNPs within loci associated with lysosomal autophagy recognized
as PD susceptibility factors by GWASs are listed in Table 4.
These genes are playing their part in general lysosomal functions,
especially lysosomal autophagy.
GBA/SYT11
GBA (beta acid glucosidase) is associated with PD susceptibility
according to several GWASs and their meta-analyses, but the
first association was found in 2011 by Do et al. (Do et al., 2011;
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TABLE 4 | SNPs within loci associated with lysosomal autophagy recognized as PD susceptibility factors by GWASs.
Gene/locus SNP MAF (1000 genomes project) Risk allele: OR Study
GBA/SYT11 Ch 1 rs35749011 g.155135036G>A (intergenic variant) A = 0.0054 A: OR = 1.824 Nalls et al., 2014
i4000416 g.155205634T>C c.1226A>C
p.Asn409Ser (missense variant)
C = 0.0006 C: OR = 4.05 Do et al., 2011
rs1630500 g.154855055G>A (intergenic variant) A = 0.0559 OR = 1.75 Vacic et al., 2014
rs12726330 g.155108167G>A c.-262G>A (splice
region variant)
A = 0.0052 OR = 1.71 Pankratz et al., 2012
rs34372695 g.156030037C>T c.-1155C>T
(upstream gene variant)
T = 0.0088 T: OR = 1.47 Nalls et al., 2011
SCARB2/FAM47E Ch 4 rs6812193 g.77198986C>T c.871-236C>T (intron
variant)
T = 0.3133 C: OR = 1.1 Nalls et al., 2014
C: OR = 1.19 Do et al., 2011
C: OR = 1.12 Simon-Sanchez et al., 2009
Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
Pankratz et al., 2012; Nalls et al., 2014; Vacic et al., 2014). On the
other hand, SYT11 (synaptotagmin XI) was confirmed as a PD
risk gene by Nalls et al. in 2011 (Nalls et al., 2011, 2014). No SNP
has been replicated in a later study.
GBA is located within the inner lysosomalmembrane, where it
cleaves membrane glucocerebrosides into ceramide and glucose.
Functional studies have shown that any kind of reduction in
GBA enzymatic activity leads to the accumulation of SNCA
which, in turn, inhibits the function of normal GBA, causing
the additional aggregation of SNCA. The authors hypothesize
that the reduction of GBA function, either caused by GBA
mutations or impaired GBA trafficking from ER and Golgi to
lysosomes, increases the glucocerebrosides concentration in lipid
rafts. This change in membrane composition may lead to the
reduced formation of LAMP2A (chaperone-mediated autophagy
receptor) protein-complexes, which could result in diminished
autophagy of SNCA and its accumulation. GBA dysfunction
may also lead to general disruption in lysosomal function and
autophagy. Furthermore, it can also be the reason for defective
mitophagy and mitochondrial damage. It was also shown that
PD patients with no mutation in the GBA may have a lower
enzyme activity. This implies that other factors may also affect
the GBA function, for example environmental factors (Gan-Or
et al., 2015).
SYT11 encodes a calcium-sensing protein involved in
membrane trafficking in synaptic transmision and is also a
substrate of Parkin, which is a risk factor for the familial form
of PD. Due to its ability of calcium-dependent phospholipid
binding, it is important in the regulation of vesicle fusion and
endocytosis at synaptic terminals (Ran and Belin, 2014). More
studies will have to be performed in order to properly determine
the function of the gene.
SCARB2/FAM47E
SCARB2/FAM47E (scavenger receptor class B member 2) locus
was first found to be associated with PD in 2009 by Simon-
Sanchez et al.; this was later confirmed by two other GWASs—Do
et al. and Nalls et al. The same SNP (rs6812193) was pointed out
in all three studies (Simon-Sanchez et al., 2009; Do et al., 2011;
Nalls et al., 2014).
SCARB2 encodes the lysosomal membrane protein type 2
(LIMP-2), which is a GCase receptor. It directs GBA to lysosomes.
The reduced function of SCARB2 can lead to a reduced GBA
activity and decreased SNCA degradation (Gan-Or et al., 2015).
The receptor, being an enterovirus 71 receptor, also plays a role in
the neuroinflammation process (Dzamko et al., 2015). FAM47E
lies in close proximity to SCARB2 and the most frequently
associated SNP (rs6812193) is situated between the two genes.
However, among the two, SCARB2 seems to be a more promising
candidate for a PD risk factor (Do et al., 2011; Ran and Belin,
2014).
Immune System
SNPs within loci associated with the immune system recognized
as PD susceptibility factors by GWASs are listed in Table 5. The
genes’ function in PD susceptibility and pathology should be
tested in a more targeted way with the help of cell and animal
models. There are some indications that genes mentioned below
play a role in the immune system, but we do not know to what
extent and if this is their main purpose, except for HLA-DQB1
whose function is quite well determined. There is also a need for
more association studies especially for STK39, HLA-DQB1 and
DDRGK1.
BST1
BST1 (bone marrow stromal cell antigen-1) was recognized as
a PD risk factor in the Satake et al. GWAS in 2009 and after
that in several other GWASs. Three intron variants were found
to be associated with PD risk. Two of them (rs11724635 and
rs4698412) were replicated in a later study (Satake et al., 2009;
Nalls et al., 2011, 2014; Saad et al., 2011; Pankratz et al., 2012).
BST1, a member of the CD38 gene family, is a cell surface protein
bound to the membrane by glycosylphosphatidylinositol linkage;
it possesses both ADP ribosyl cyclase and cyclic ADP ribose
hydrolase enzymatic activities. It produces cyclic ADP-ribose,
which as a second messenger releases calcium from intracellular
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TABLE 5 | SNPs within loci associated with immune system recognized as PD susceptibility factors by GWASs.
Gene/locus SNP MAF (1000 genomes project) Risk allele: OR Study
BST1 Ch 4 rs11724635 g.15737101C>A (intron variant) A = 0.4079 A: OR = 1.126 Nalls et al., 2014
A: OR = 1.15 Nalls et al., 2011
rs4538475 g.15737937A>G c.*195A>G (intron variant) G = 0.3089 OR = 1.24 Satake et al., 2009
rs4698412 g.15737348G>A c.852-328G>A (intron variant) A = 0.4077 OR = 1.14 Pankratz et al., 2012
A: OR = 1.14 Saad et al., 2011
STK39 Ch 2 rs1474055 g.169110394C>T (intergenic variant) T = 0.2007 T: OR = 1.214 Nalls et al., 2014
rs2102808 g.169117025G>T (intergenic variant) T = 0.2083 C: OR = 1.18 Nalls et al., 2011
HLA-DQB1 Ch 6 rs9275326 g.32666660C>T (intergenic variant) T = 0.0843 C: OR = 1.21 Nalls et al., 2014
DDRGK1 Ch 20 rs8118008 g.3168166A>G (downstream gene variant) G = 0.4597 A: OR = 1.111 Nalls et al., 2014
Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
*Denotes SNPs in 3’-UTR.
ER stores, leading to calcium influx. Calcium is a great
regulator of neurotransmitter release from presynaptic terminals;
therefore, a disruption in neuronal calcium homeostasis could
lead to selective death of dopaminergic neurons. Interestingly,
BST1 seems to be an important factor in the immune system,
since it is highly expressed in bone marrow cells in patients with
rheumatoid arthritis and facilitates immature B-cell proliferation
and growth (Chen et al., 2014; Ran and Belin, 2014).
STK39
STK39 (serine threonine kinase 39) is highly expressed in the
brain and pancreas (Wang et al., 2014). It codes for a SPAK
protein (Ste20-related proline/alanine rich-kinase) (Kumaran
and Cookson, 2015). As a PD risk factor, it was first described
by Nalls et al. in 2011 and then again confirmed three years
later by the same group. Two different intergenic variants were
pointed out in these studies (Nalls et al., 2011, 2014). It is
a serine/threonine kinase, which is activated under cellular
stress and plays a role in stress signals, ion homeostasis and
inflammation (Li et al., 2013; Ran and Belin, 2014). It has
been shown that its overexpression alters intestinal inflammatory
levels in mouse models of colitis, whereas its knockout attenuates
intestinal inflammation (Dzamko et al., 2015; Kumaran and
Cookson, 2015). Apart from PD, it has been associated with
hypertension, autism and early-stage non-small-cell lung cancer
(Li et al., 2013).
HLA-DQB1
HLA-DQB1 (major histocompatibility complex, class II, DQ
beta 1) was shown to be associated with the risk for PD in the
Nalls et al. study in 2014 (Nalls et al., 2014). Only one intergenic
variant was shown to be associated with a PD risk, which means
that more association studies confirming the association need
to be conducted. It plays a key role in the immune system by
presenting peptides to the antigen presenting cells. The HLA
region is one of the most complex regions in the genome.
It encompasses a high number of closely packed genes, with
numerous polymorphisms and complicated patterns of linkage
disequilibrium. As part of immune response HLA genes, are
involved in many pathologies, such as autoimmune diseases,
infections and malignant and neurological disorders. The HLA
region is divided into classes, I and II, but they both code for
proteins that present antigens to T cell receptors as part of the
adaptive immune system. HLA class II molecules are expressed
in antigen presenting cells—macrophages, B lymphocytes and
dendritic cells. They consist of two chains, alpha (DQA) and beta
(DQB) (Lampe et al., 2003; Wissemann et al., 2013; Chang et al.,
2015). Several HLA genes (Hill-Burns et al., 2011) are thought
to be associated with PD, besides HLA-DQB1 also HLA-DRA
(Hamza et al., 2010; Pankratz et al., 2012; Hill-Burns et al., 2014)
and HLA-DRB (Ahmed et al., 2012).
DDRGK1
DDRGK1 (DDRGK domain containing 1) gene was found to be
associated with PD in the meta-analysis of GWASs performed by
Nalls et al. (2014), but the association has not been confirmed
yet. DDRGK1 regulates the nuclear factor-κB (NF-κB) activity
(Dzamko et al., 2015). NF-κB is a group of inducible nuclear
transcription factors; it is largely expressed in a wide variety of
cells and regulates the expression of a lot of genes in response
to different stimuli. It plays an important role in inflammation,
immune system as well as in tumorigenesis (Mitchell et al., 2016).
DDRGK1 is localized in the endoplasmic reticulum (ER) and its
expression is induced by ER stress (Xi et al., 2013).
Neurodevelopment, Neuron Cell
Differentiation and Survival
SNPs within loci associated with neurodevelopment, neuron
cell differentiation and survival recognized as PD susceptibility
factors by GWASs are listed in Table 6.
CCDC62
CCDC62 (coiled-coil domain containing 62) was found to be
related to PD susceptibility in the Nalls et al. studies conducted in
2011 and 2014 (Nalls et al., 2011, 2014) pointing out two different
intron variants. The gene has a role in cell growth, estrogen
receptor transactivation, cyclin D1 expression in prostate cancer
cells as well as in other varieties of cancer, since its antibodies are
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TABLE 6 | SNPs within loci associated with neurodevelopment, neuron cell differentiation and survival recognized as PD susceptibility factors by GWASs.
Gene/locus SNP MAF (1000 genomes project) Risk allele: OR Study
CCDC62 Ch 12 rs11060180 g.123303586A>G c.2002-4327A>G (intron variant) G = 0.2516 A: OR = 1.105 Nalls et al., 2014
rs12817488 g.123296294G>A c.1852-1523G>A (intron variant) A = 0.4159 T: OR = 1.14 Nalls et al., 2011
RIT2 Ch 18 rs12456492 g.43093415A>G c.103+22002T>C (intron variant) G = 0.3297 G: OR = 1.11 Nalls et al., 2014
OR = 1.19 Pankratz et al., 2012
rs4130047 g.43098270T>C c.103+17147A>G (intron variant) C = 0.3237 C: OR = 1.16 Do et al., 2011
FGF20 Ch 8 rs591323 g.16697091G>A (intron variant) A = 0.3652 G: OR = 1.09 Nalls et al., 2014
GCH1 Ch 14 rs11158026 g.55348869C>T c.344-16715G>A (intron variant) C = 0.4898 C: OR = 1.11 Nalls et al., 2014
GPNMB Ch 2 rs199347 g.23293746A>G c.224-42A>G (intron variant) A = 0.4832 A: OR = 1.11 Nalls et al., 2014
Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
often produced and thus detected (Li et al., 2013; Lu et al., 2016).
Until recently, it was mainly reported as related to cancer (Yu
et al., 2015). In order to define the gene’s function more precisely,
more functional studies are required.
RIT2
RIT2 (ras-like without CAAX 2) was first described as a PD
susceptibility factor in the GWAS performed by Do et al. in
2011 and after that confirmed in two meta-analyses (Pankratz
et al., 2012; Nalls et al., 2014). Two variants within the gene
were found to be associated with the PD risk. One of them
(rs12456492) was replicated, while the other (rs4130047) was
significant in only one study (Do et al., 2011; Pankratz et al., 2012;
Nalls et al., 2014). RIT2 is a small GTPase of the Ras family. It
is neuron-specific and preferentially expressed in dopaminergic
neurons in substantia nigra (Ran and Belin, 2014). Accumulating
reports suggest its important role in neuronal differentiation
and function. It promotes neurite outgrowth through Rac/Cdc42
activation and calmodulin association (Zhang et al., 2013). It
binds calmodulin 1, a phosphorylase kinase, in a calcium-
dependent manner and regulates certain signaling pathways and
cellular processes (Do et al., 2011). It interacts with SNCA and
tau via calmodulin (Lu et al., 2015). RIT2 is also a specific
interacting partner of the dopamine transporter (DAT). DAT is
a transmembrane protein which can be internalized by protein
kinase C-mediated endocytosis and thus downregulated. It was
proposed that extracellular dopamine concentrations and half-
life are regulated in this manner. This process presumably
depends on RIT2 GTPase activity (Zhang et al., 2013; Ran and
Belin, 2014). A reduced production of RIT2 was detected in
postmortem samples of PD patients when compared to controls
(Bossers et al., 2009). In another postmortem study, a possible
regulation of INF-γ signaling by RIT2 was discovered (Liscovitch
and French, 2014).
FGF20
FGF20 (fibroblast growth factor 20) was proved to be associated
with PD in the Nalls et al. meta-analysis (Nalls et al., 2014),
in which one intron variant within the gene with a positive
association was found. More studies will have to be done
to confirm this association. FGF20 is a neurotrophic factor
preferentially expressed in substantia nigra pars compacta. It
acts in an autocrine/paracrine manner. FGF20 regulates central
nervous development and function (Plagnol et al., 2011). It plays
amajor role in dopaminergic neurons differentiation and survival
(Itoh and Ohta, 2013). According to some studies, FGF20 also
increases SNCA levels in dopaminergic neurons, but there is a
huge discrepancy among studies (Wang et al., 2008; Wider et al.,
2009; Sekiyama et al., 2014; Tarazi et al., 2014).
GCH1
GCH1 (GTP cyclohydrolase 1) was found to be associated with
PD pathology only in the Nalls et al. meta-analysis of GWASs
(Nalls et al., 2014), which means that more studies whose results
will show a positive association are required to claim that the
association is in fact true. GCH1 is an essential enzyme in
dopamine synthesis in the nigrostriatal nervous cells. Mutations
in this gene can result in the degeneration of nigral neurons.
Loss of function leads to severe depletion of dopamine levels
and is the most frequent cause of DOPA-responsive dystonia
(DRD), a rare disease that classically occurs during the childhood
and is manifested as generalized dystonia and an excellent
sustained response to low doses of levodopa, usually without
motor fluctuations. DRD is often associated with PD. Mutations
in the gene might cause striatal cell death and thus evolve into
PD. The enzyme controls the first and rate-limiting step in the
biosynthesis of tetrahydrobiopterin (BH4), which is a cofactor
of tyrosine hydroxylase, which converts tyrosine to levodopa
(Mencacci et al., 2014; Rengmark et al., 2016). It may also have
some role in inflammation (Dzamko et al., 2015). The debate on
whether this gene is related to the familial or sporadic form is still
ongoing. Some say that PD-like symptoms in adulthood could
also be a different phenotype of DRD.
GPNMB
GPNMB (glycoprotein nonmetastatic melanoma protein B) was
recognized as associated with a PD risk in the Nalls et al.
meta-analysis in 2014. As the association was found in one
study only, we cannot conclude that the association is definite
(Nalls et al., 2014). It presumably plays an important role in
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TABLE 7 | SNPs within loci associated with mitochondrial homeostasis recognized as PD susceptibility factors by GWASs.
Gene/locus SNP MAF (1000 genomes project) Risk allele: OR Study
SREBF1/RAI1 Ch 17 rs11868035 g.17715101G>A c.*835C>T (splice region variant) G = 0.4876 G: OR = 1.18 Do et al., 2011
MCCC1 Ch 3 rs12637471 g.182762437G>A c.732+764C>T (intron variant) A = 0.3375 G: OR = 1.1876 Nalls et al., 2014
rs11711441 g.182821275G>A (intron variant) A = 0.1406 G: OR = 1.19 Nalls et al., 2011
rs10513789 g.182760073T>G c.733-535A>C (intron variant) G = 0.3115 T: OR = 1.25 Do et al., 2011
Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
*Denotes SNPs in 3’-UTR.
neuronal survival and neuroprotection (Xu et al., 2016). It
is also known as osteoactivin, dendritic cell-heparin integrin
ligand or haematopoietic growth factor inducible neurokinin-
1 type. It is important for the differentiation and functioning
of osteoclasts and osteoblasts, the impairment T-cell activation,
the invasion, and metastasis of many cancers and the regulation
of degeneration/regeneration of extracellular matrix in skeletal
muscles. The gene was also associated with amyotrophic lateral
sclerosis as another type of a neurodegenerative disease (Tanaka
et al., 2012). The protein mostly localizes in lysosomes. It is
also involved in phagocytosis and helps to recruit an autophagy
protein LC3-II to the phagosome. It is essential for the fusion
of phagosome and lysosome to degrade the phagosome content
(Gan-Or et al., 2015). GPNMB is somehow involved in innate
and adaptive immunity along with many PD susceptibility
factors. It may play a role in regulating microglial inflammation
downstream of LPS activation (Dzamko et al., 2015; Herrero
et al., 2015).
Mitochondrial Homeostasis
SNPs within loci associated with mitochondrial homeostasis
recognized as PD susceptibility factors by GWASs are listed in
Table 7.
SREBF1/RAI1
SREBF1/RAI1 (sterol regulatory element binding transcription
factor 1/retinoic acid induced 1) locus was associated with PD
susceptibility for the first time by Do et al. GWAS (Do et al.,
2011). In 2014, it was again confirmed by the meta-analysis of
GWASs (Nalls et al., 2014). The same SNP (rs11868035) was
pointed out in both studies.
SREBF1 encodes SREBP-1 (sterol regulatory element-binding
protein 1), a transcriptional activator (Do et al., 2011). The
connection of mitophagy pathway and familial PD has been
firmly established via two genes—PINK1 and Parkin, but also
GWASs and functional studies found the association between
this pathway and sporadic PD through SREBF1. It is involved
in the mitophagy as well as in the regulation of lysosomal
lipid accumulation. Mitochondria and lipid metabolism have
complementary functions via Krebs cycle. Knockdown of
SREBF1 blocks the translocation of Parkin into the mitochondria
and consequently decreases mitophagy (Gan-Or et al., 2015).
This process can be restored by the addition of exogenous lipids,
both fatty acids and cholesterol. Downregulation of SREBF1may
also decrease mitophagy by blocking the stabilization of PINK1
on the outer mitochondrial membrane of injured mitochondria,
which can also be repaired by additional exogenous lipids (Ivatt
and Whitworth, 2014). It regulates cholesterol synthesis and
its cellular uptake from plasma LDL. A reduced expression
of SREBF1 also downregulates the NPC1 gene, which may
lead to the accumulation of cholesterol within late endosomes
and lysosomes (Gan-Or et al., 2015). Autophagic turnover of
mitochondria needs to be balanced with its biogenesis, which
heavily relies upon SREBP pathway for membrane synthesis
(Ivatt et al., 2014). Some studies also suggest that SREBP-1 is an
important mediator of NMDA-induced excitotoxicity (Do et al.,
2011). It may also be involved in the innate immune response via
lipid metabolism (Jeon and Osborne, 2012).
RAI1 is a part of transcription regulation mechanism, beacuse
it has the ability to remodel chromatin and interacts with the
basic transcriptional machinery (Do et al., 2011).
MCCC1
MCCC1 [methylcrotonyl-CoA carboxylase 1 (alpha)] was shown
to be associated with sporadic PD in 2011 with two GWASs
and after that again confirmed with the meta-analysis. In all
three studies, a different intron variant was implicated as a risk
factor (Do et al., 2011; Nalls et al., 2011, 2014). Its product, a
biotin-requiring enzyme, functions within the mitochondria as
a part of leucine catabolism pathway (Wang et al., 2014). It is
currently not known if this enzyme has a role in the mitophagy
or mitochondrial quality control. Researchers are also debating
on whether this gene or rather LAMP3 located on the same locus
is involved in PD pathogenesis (Gan-Or et al., 2015).
Other Processes
SNPs within loci associated with other processes recognized as
PD susceptibility factors by GWASs are listed in Table 8. More
association and functional studies will have to be performed
to discover a clear connection between a PD risk and genes
mentioned below.
ACMSD/TMEM163
ACMSD/TMEM 163 (aminocarboxymuconate semialdehyde
decarboxylase-transmembrane protein 163) was shown to be
associated with PD by Nalls et al. studies as well as by Pankratz
et al. meta-analysis of GWASs. Two variants were found in
these three studies, which means that one of them (rs6430538)
was also replicated (Nalls et al., 2011, 2014; Pankratz et al.,
2012). This gene is expressed at very low but significant levels
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TABLE 8 | SNPs within loci associated with other processes recognized as PD susceptibility factors by GWASs.
Gene/locus SNP MAF (1000 genomes project) Risk allele: OR Study
ACMSD/TMEM163 Ch 2 rs6430538 g.135539967C>T (intron variant) C = 0.1891 C: OR = 1.1429 Nalls et al., 2014
OR = 1.15 Pankratz et al., 2012
rs6710823 g.135592381G>A (intron variant) NA G: OR = 1.1 Nalls et al., 2011
MIR4697 Ch 11 rs329648 g.133895472T>C (downstream gene variant) T = 0.4645 T: OR = 1.105 Nalls et al., 2014
SIPA1L2 Ch 1 rs10797576 g.232664611C>T (intron variant) T = 0.1274 T: OR = 1.131 Nalls et al., 2014
NA, data not available; Ch, Chromosome. Data compiled from the GWAS catalog database, the dbSNP and the e!Ensembl (Sherry et al., 2001; Welter et al., 2014; Yates et al., 2016).
in the brain and encodes a cytosolic enzyme (Martí-Massó et al.,
2013). ACMSD is involved in the picolinic and quinolinic acid
homeostasis and is thus a possible therapeutic target for many
central nervous system disorders (Plagnol et al., 2011). ACMSD
is also categorized as a detoxifying enzyme because of its ability to
prevent the accumulation of neurotoxic metabolite quinolinate,
which is one of the tryptophan catabolites (Ran and Belin, 2014).
It also participates in the kynurenine pathway of tryptophan
catabolism. Mutations in the gene presumably result in a
decreased enzymatic activity, which means that the conversion of
tryptophan to picolinic acid is blocked. Consequently, quinolinic
acid levels in the brain are elevated. Quinolinat is also an
intermediate of the de novo synthesis of NAD from tryptophan
(Martí-Massó et al., 2013).
MIR4697
MIR4697 is a non-protein coding sequence that was shown to be
associated with PD in the Nalls et al. meta-analysis in 2014 (Nalls
et al., 2014) in which one SNP with a positive association was
found. The function of the microRNA in general is not known,
much less its function in PD pathology (Chen et al., 2016).
SIPA1L2
SIPA1L2 (signal-induced proliferation-associated 1 like 2) is a
gene related to PD pathogenesis according to the Nalls et al.
study conducted in 2014, but the function of the gene has to be
determined yet. Only one SNP has been pointed out as a risk
factor so far (Nalls et al., 2014).
APPLICABILITY OF THE KNOWLEDGE
ABOUT GENETIC SUSCEPTIBILITY
FACTORS FOR PD
The knowledge about the genetic factors of PD risk or
pathogenesis related to a specific pathway could be applied in
the clinical setting to support early diagnosis and to predict
disease prognosis as suggested by the study of Nalls et al. (2015).
Furthermore, the information on susceptibility genes could be
easily integrated in composite diagnostic and/or prognostic
algorithms that at present include clinical characteristics and
imaging data (Siderowf et al., 2012; Gaenslen et al., 2014;
Noyce et al., 2014). These genetic factors could also help to
stratify the patients on the basis of underlying molecular defect
into respective groups that would benefit from targeting a
specific pathway with novel or existing treatment approaches,
which would enable personalized treatment planning. The
latter also indicates an opportunity to identify novel potential
targets for innovative treatment approaches and supportive
measures.
First, described genetic factors could support early diagnosis.
This is an important goal for clinicians dealing with PD, because
it is important to start treatment early in the disease course
(Olanow and Schapira, 2013). It would be ideal to identify
patients in the prodromal phase of the disease (Berg et al.,
2015). By the time motor symptoms occur, more than half
of dopaminergic neurons are already lost. The time of the
prediagnostic phase, which can last for up to 20 years, thus
presents the window of opportunity for searching for and for
the application of neuroprotective treatment (Salat et al., 2016).
For the purpose of early diagnosis, a panel of genes should be
tested for different mutations and polymorphisms to check the
cumulative effect of the genetic defects as a single mutation
or polymorphism has a very low contribution to disease risk.
The combined assessment of early non-motor symptoms with
a genetic predisposition could be an ideal method to identify
the patients in the earliest phases of the disease. Only genetic
testing for diagnosis of sporadic PD or for the prediction of
developing sporadic PD is not specific and sensitive enough at
the moment. There is no known genetic factor or combination of
genetic factors that could conclusively predict the development
of sporadic PD. Therefore, genetic testing would probably be
more suitable for high risk families with positive PD history or
for people with manifestations of early non-motor symptoms
and not for general population. Furthermore, a cumulative
score and not individual genetic factors should be considered,
jointly with clinical and imaging data. Nalls et al. developed
an algorithm for early diagnosis of PD on the basis of clinical
and genetic classification. Their model included several clinical
factors, such as age, gender, olfactory function and family history
of PD. They combined clinical factors with a genetic risk score,
that accounted for 28 genetic variants identified and replicated
in the most recent large-scale meta-analysis of PD GWASs
data plus two other rare risk variants, a GBA (rs76763715)
and a LRRK2 (rs34637584) mutation. The model correctly
distinguished between patients with PD and controls with an
area under curve of 0.923 with both high sensitivity (0.834) and
specificity (0.903). They also validated the model on five other
cohorts and AUC was never lower than 0.894 (Nalls et al., 2015).
There are a few prospective longitudinal studies running (PARS,
TREND, PREDICT-PD), which are looking for biomarkers to
identify PD and predict the way of disease progression before
a diagnosis based on motor symptoms can be made, and
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assessing combinations of risk factors and early features of PD.
Among these studies, PARS included a cohort of elderly patients
with olfactory dysfunction, TREND included people older than
50 years with one of prodromal symptoms of PD (olfactory
dysfunction, REM sleep behavior disorder or depression), while
PREDICT-PD included general population from 60 to 80 years
of age irrespective of PD prodromal symptoms (Salat et al.,
2016).
Furthermore, the impact of genetic susceptibility factors
on the disease prognosis could be evaluated. It would
be interesting to explore the association between the
course of the disease and the genetic defect in genes
involved in certain pathways. For example, GBA mutations
or MAPT H1 allele status might be independent risk
factors for cognitive impairment in PD patients and the
knowledge of these allele statuses in patients could have an
impact on the treatment plan (Clarimón and Kulisevsky,
2013).
Moreover, genetic susceptibility factors segregating in
different pathways could help to stratify PD patients into distinct
groups according to the differences in the main molecular
cause of the disease. So far, the stratification of patients has
only been made based on different phenotypes (van Rooden
et al., 2010, 2011; Fereshtehnejad et al., 2015), but our main
idea is to group them on the basis of the main molecular cause
of the disease rather than on the basis of different ways of
manifestation. The stratification should be based on cumulative
effects of genetic susceptibility factors within a particular
pathway as well as across pathways, so different combinations
of genetic defects should be tested to find a way to stratify
the PD patients. This approach was already addressed in a
review written by Schapira et al. (Schapira, 2013), where the
problem of aetiologically heterogeneous cohorts of PD patients
evaluated in different studies was exposed. The latter makes
it difficult to seek for different genetic biomarkers as there
may be different ones in distinct groups. The stratification of
PD patients based on underlying genetic defects could also
be beneficial in a clinical setting as patients with different
genetic defects may need different treatment plans. This kind
of personalized treatment could become the treatment of
choice in PD in the future, as we could stratify patients into
groups according to their compromised pathway and treat
them according to their underlying pathogenic processes. The
treatment could be adjusted for each group to obtain the best
possible response.
Last but not least, the disease genes or the products of
the genes involved in the aethiopathogenesis could serve as
novel targets for neuroprotective or disease-modifying drugs to
delay or prevent disease progression. However, the problem of
a very modest impact of the above-mentioned mutations and
polymorphisms on the PD pathology occurs. If the impact of
a single mutation is very low, there is probably no point in
developing a new active pharmaceutical agent specific for that
target, because the effect on the disease course would probably
not be satisfactory. A more feasible way of incorporating means
of personalized medicine and patient startification into PD
management is to target a corrupted pathway as a whole instead
of focusing only on the compromised gene and its product.
The goal would be to strengthen or improve the function of
a compromised pathway, such as protein aggregation; protein
and membrane trafficking; lysosomal autophagy; immune
system; neurodevelopment, neuron cell differentiation and
survival; mitochondrial homeostasis; and genes involved in other
processes. Although this is a less specific approach, it focuses
on the putative main cause of the disease occurrence in a
particular patient. In the light of this, there is a possibility of
the repurposing of drugs already used for other indications,
for example ursodeoxycholic acid, nicotine, caffeine, isradipine,
exenatide, statins (Salat et al., 2016). In order to establish
such a pathway-oriented approach, clinical trials must focus
on PD patients with the same underlying molecular defect. As
long as heterogenous cohorts are evaluated in these studies,
no such treatment will be available (Korczyn and Hassin-Baer,
2015).
FUTURE PERSPECTIVES
With the emergence of GWASs, researchers believed that the
discovery of the exact genetic background of PD is at their
fingertips, but more questions arose afterwards. GWASs are
a type of studies with no hypothesis at the time of their
performance, so the results must be critically evaluated and
supported by functional studies of genes recognized to be
involved in the pathogenesis of a certain disease. Apart from
functional studies of not yet known genes’ functions, animal
disease models should also be investigated to check and validate
the results of GWASs. We also have to be aware of the
fact, that GWAS usually detect common SNPs that most
probably have a modest impact only. Rare but highly penetrant
SNPs are often overlooked. Hence, in terms of susceptibility
prediction or early diagnosis, physicians should check several
genetic biomarkers (SNPs) and their cumulative impact on the
prognosis along with clinical and imaging data. Additionally,
SNPs associated with a certain disease are often not located
within the disease gene, but are rather in linkage disequlibrium
with it.
The main goal of searching for genetic biomarkers of
PD susceptibility is early diagnosis or more optimistically,
a chance to slow down or even prevent the development
of the disease. Furthermore, with better characterization of
risk genes’ functions, we could stratify the PD patients into
groups according to the main route of pathogenesis. Prospective
monitoring is needed to compare the symptomatology as
well as the rate of progression between the groups in
order to get a chance of tailoring the therapy to each
group. To take this idea to the next level, one could also
find new drug targets based on the susceptibility genes
or their products if the impact of the susceptibility gene
is high enough. A personalized approach would allow to
treat each group of patients with the most effective and
safest drug and adopt optimal supportive measures, e.g.,
antiinflammatory therapy for patients with an increased
inflammatory response.
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CONCLUSIONS
In conclusion, the newest GWASs have identified top hit
susceptibility genes with emerging information on their
physiological functions and involvement in PD pathology. These
susceptibility genes belong to specific pathways that are already
known to be compromised in PD and could thus serve as a
genetic tool for the stratification of patients. In our opinion,
this would allow the treatment of patients according to the
underlying cause of their clinical signs to choose the most
beneficial treatment with minimal side effects. This knowledge
gives the opportunity to personalize the treatment of PD patients,
but more studies need to be carried out on cell models, animal
models and patients before new knowledge can be translated
into the everyday clinical practice of PD treatment.
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